Clostridium-difficile-Infektion

Schlüsselwörter

Clostridium difficile - pseudomembranöse Kolitis - Diarrhoe

Keywords

Clostridium difficile - Clostridium difficile-associated colitis - diarrhea

Literatur

• 1 Al-Nassir W N, Sethi A K, Li Y, Pultz M J, Riggs M M, Donskey C J. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease.  Antimicrob Agents Chemother. 2008;  52 2403-2406
• 2 Al-Nassir W N, Sethi A K, Nerandzic M M, Bobulsky G S, Jump R L, Donskey C J. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.  Clin Infect Dis. 2008;  47 56-62
• 3 Bakken J S. Faecal bacteriotherapy for recurrent Clostridium difficile infection.  Anaerobe. 2009;  15 285-289
• 4 Bartlett J G, Chang T W, Gurwith M. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia.  N Engl J Med. 1978;  298 531-534
• 5 Bauer M P, van Dissel J T, Kuijper E J. Clostridium difficile: controversies and approaches to management.  Curr Opin Infect Dis. 2009;  22 517-524
• 6 Belmares J, Gerding D N, Parada J P. et al . Outcome of metronidazole therapy for Clostridium difficile disease and correlation with a scoring system.  J Infect. 2007;  55 495-501
• 7 Blondeau J M. What have we learned about antimicrobial use and the risks for Clostridium difficile-associated diarrhoea?.  J Antimicrob Chemother. 2009;  63 238-242
• 8 Burckhardt F, Friedrich A, Beier D, Eckmanns T. Clostridium difficile surveillance trends, Saxony, Germany.  Emerg Infect Dis. 2008;  14 691-692
• 9 Gerding D N, Muto C A, Owens Jr R C. Treatment of Clostridium difficile infection.  Clin Infect Dis. 2008;  46 Suppl 1 S32-S42
• 10 Grünewald T, Frenzel S, Decker M, Lindner B, Sultzer R, von Eichel-Streiber C, Ruf B R. Nosokomiale Epidemiologie und Transmission der Clostridium difficile-Infektion.  Dtsch Med Wochenschr. 2001;  126 519-522
• 11 Johnson S. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.  J Infect. 2009;  58 403-410
• 12 Kist M, Bockemühl J, Aleksic S. et al .Infektionen des Darms. In: Mauch H, Lütticken R, Gatermann S Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. Stuttgart Jena Lübeck Ulm: Gustav Fischer; 2000: 1-62
• 13 Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev; 2007 ; CD004610
• 14 Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev; 2008 ; CD004611
• 15 Raveh D, Rabinowitz B, Breuer G S. et al . Risk factors for Clostridium difficile toxin-positive nosocomial diarrhoea.  Int J Antimicrob Agents. 2006;  28 231-237
• 16 Reichardt C, Chaberny I F, Kola A, Mattner F, Vonberg R P, Gastmeier P. Dramatischer Anstieg von Clostridium-difficile-assoziierter Diarrhö in Deutschland.  Dtsch Med Wochenschr. 2007;  132 223-228
• 17 Robert-Koch-Institut. Ratgeber Infektionskrankheiten – Merkblätter für Ärzte: Clostridium difficile.  Epidemiol Bull. 2009;  24 233-239
• 18 Schneider T, Eckmanns T, Ignatius R, Weist K, Liesenfeld O. Clostridium-difficile-assoziierte Diarrhö: Ein zunehmendes klinisches Problem durch neue hochvirulente Erreger.  Dtsch Ärztebl. 2007;  104 A-1588
• 19 Surawicz C M. Treatment of recurrent Clostridium difficile-associated disease.  Nature Clin Pract Gastroenterol Hepatol. 2004;  1 32-38
• 20 Vonberg R P, Schwab F, Gastmeier P. Clostridium difficile in discharged inpatients, Germany.  Emerg Infect Dis. 2007;  13 179-180